Document is current
Any future updates will be listed below
-
Authors
Hawke, Lisa D.
Nguyen, Anh T. P.
Sheikhan, Natasha Yasmin
Strudwick, Gillian
Rossell, Susan L.
Soklaridis, Sophie
Kloiber, Stefan
Shields, Roslyn
Ski, Chantal F.
Thompson, David R.
Castle, David
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
- License Information
-
More Information
Article History
Received: 23 May 2023
Accepted: 29 September 2023
First Online: 11 October 2023
Declarations
:
: The study has received ethical approval from the Centre for Addiction and Mental Health Research Ethics Board (#030-2022). The study was conducted in compliance with all relevant guidelines and regulations. All participants have provided written informed consents prior to completing the focus groups.
: All participants have provided written consents for the research team to use their de-identified data in this manuscript, including information provided through demographic surveys and quotations from the focus groups.
: SLR holds a Senior National Health and Medical Research Council (NHMRC) Fellowship (GNT1154651) in Australia. SK reports grants from the Labatt Family Innovation Fund in Brain Health (Department of Psychiatry, University of Toronto), the Max Bell Foundation, the Canadian Centre on Substance Use and Addiction, the Ontario Ministry of Health and Long-Term Care (MOHLTC), the Canadian Institutes of Health Research (CIHR). David Castle has received grant monies for research from Servier, Boehringer Ingelheim; Travel Support and Honoraria for Talks and Consultancy from Servier, Seqirus, Lundbeck. He is a founder of the Optimal Health Program (OHP), and holds 50% of the IP for OHP; and is part owner of Clarity Healthcare. He does not knowingly have stocks or shares in any pharmaceutical company. Other authors have no conflict of interest to declare.
